



**Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2014
(Three Months Ended March 31, 2014)**

[Japanese GAAP]

May 2, 2014

Company name: tella, Inc. Stock Exchange Listing: Tokyo Stock Exchange (JASDAQ)
 Stock code: 2191 URL: <http://www.tella.jp/>
 Representative: Yuichiro Yazaki, President & Representative Director
 Contact: Kazuyuki Yamamoto, Executive Officer, General Manager, TEL: +81-3-5572-6590
 Public Relations and Investor Relations Department
 Scheduled submission of Quarterly Report: May 2, 2014
 Scheduled date of dividend payment: -
 Preparation of supplementary materials for quarterly financial results: None
 Holding of quarterly financial results meeting: None

Note: The original disclosure in Japanese was released on May 2, 2014 at 15:30 (GMT +9).

(All amounts are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Three Months Ended March 31, 2014 (Jan. 1, 2014 to Mar. 31, 2014)

(1) Consolidated results of operations (Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended Mar. 31, 2014	328	(5.4)	(106)	-	(123)	-	(84)	-
Three months ended Mar. 31, 2013	347	4.1	28	23.3	27	29.3	13	48.1

Note: Comprehensive income (millions of yen) Three months ended Mar. 31, 2014: (86) (n.a.)

Three months ended Mar. 31, 2013: 15 (up 38.8%)

	Net income per share	Diluted net income per share
	Yen	Yen
Three months ended Mar. 31, 2014	(6.15)	-
Three months ended Mar. 31, 2013	1.02	1.01

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of Mar. 31, 2014	3,776	2,802	72.2
As of Dec. 31, 2013	2,387	1,529	60.8

Reference: Shareholders' equity (millions of yen) As of Mar. 31, 2014: 2,725 As of Dec. 31, 2013: 1,450

2. Dividends

	Dividend per share				
	1Q-end	2Q-end	3Q-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
FY12/2013	-	0.00	-	0.00	0.00
FY12/2014	-	-	-	-	-
FY12/2014 (Forecast)	-	0.00	-	0.00	0.00

Note: Revisions to the most recently announced dividend forecast: None

3. Consolidated Forecast for the Fiscal Year Ending December 31, 2014 (Jan. 1, 2014 to Dec. 31, 2014)

(Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First half	1,067	23.3	(78)	-	(95)	-	(97)	-	(7.38)
Full year	2,090	35.7	(135)	-	(156)	(543.6)	(154)	(165.0)	(11.68)

Note: Revision to the most recently announced consolidated forecast: None

*** Notes**

(1) Changes in significant subsidiaries during the period (change in scope of consolidation): None

(2) Application of special accounting methods for presenting quarterly consolidated financial statements: None

(3) Changes in accounting policies and accounting-based estimates, and restatements

1) Changes in accounting policies due to revisions in accounting standards, others: None

2) Changes in accounting policies other than 1) above: None

3) Changes in accounting-based estimates: None

4) Restatements: None

(4) Number of shares outstanding (common stock)

1) Number of shares outstanding at the end of period (including treasury shares)

As of Mar. 31, 2014:	13,795,156 shares	As of Dec. 31, 2013:	13,228,431 shares
----------------------	-------------------	----------------------	-------------------

2) Number of treasury shares at the end of period

As of Mar. 31, 2014:	239 shares	As of Dec. 31, 2013:	239 shares
----------------------	------------	----------------------	------------

3) Average number of shares outstanding during the period

Three months ended Mar. 31, 2014:	13,684,370 shares	Three months ended Mar. 31, 2013:	13,136,761 shares
-----------------------------------	-------------------	-----------------------------------	-------------------

Note 1: Information regarding the implementation of quarterly review procedures

At the time of disclosure, the review procedures based on the Financial Instruments and Exchange Act for the quarterly consolidated financial statements had been completed.

Note 2: Cautionary statement with respect to forward-looking statements and other special items

Forecasts regarding future performance in these materials are based on assumptions judged to be valid and information available to the Company at the time these materials were created. Actual performance may differ significantly from these forecasts for a number of reasons. Please refer to "Explanation of Consolidated Forecast and Other Forward-looking Statements" on page 4 of the attachments for forecast assumptions and notes of caution for usage.

Contents of Attachments

1. Qualitative Information on Quarterly Consolidated Financial Performance	2
(1) Explanation of Results of Operations	2
(2) Explanation of Financial Position	4
(3) Explanation of Consolidated Forecast and Other Forward-looking Statements	4
2. Matters Related to Summary Information (Notes)	4
(1) Changes in Significant Subsidiaries during the Period	4
(2) Application of Special Accounting Methods for Presenting Quarterly Consolidated Financial Statements	4
(3) Changes in Accounting Policies and Accounting-based Estimates, and Restatements	4
3. Quarterly Consolidated Financial Statements	5
(1) Quarterly Consolidated Balance Sheet	5
(2) Quarterly Consolidated Statements of Income and Comprehensive Income	7
Quarterly Consolidated Statement of Income	
For the Three-month Period	7
Quarterly Consolidated Statement of Comprehensive Income	
For the Three-month Period	8
(3) Notes to Quarterly Consolidated Financial Statements	9
Going Concern Assumption	9
Significant Changes in Shareholders' Equity	9
Segment and Other Information	9
Material Subsequent Events	10

1. Qualitative Information on Quarterly Consolidated Financial Performance

(1) Explanation of Results of OperationsIn the first quarter of 2014, the tella Group's operating environment was as follows. The promotion of regenerative medicine and cell therapy is one of the main elements of the Abenomics growth strategy. One result was the April 2013 passage of the Act concerning the Comprehensive Promotion of Measures for the Rapid and Safe Use of Regenerative Medicine in Japan. In November 2013, two more laws were passed. One is the Act concerning the Assurance of Quality, Efficacy and Safety for Pharmaceuticals and Medical Devices, which newly defines regenerative medicine products and establishes a system for quick approvals of these products with certain conditions. The other is the Act concerning the Assurance of Safety for Regenerative Medicine, which is aimed at facilitating the commercialization of cell processing operations. Overall, there is a progress toward establishing an environment for regenerative medicine and cell therapy businesses and even creating an industry for these activities.

Against this backdrop, the tella Group continued to perform R&D involving the dendritic cell (DC) vaccine Vaccell®, which is one type of cancer vaccine therapy. We conducted sales activities targeting medical institutions nationwide, and academic and information activities which include mainly using seminars and other methods to provide information to patients and making announcements at academic events. Activities also include the provision of maintenance and management services of cell processing facilities by contract chiefly to universities and research institutions, sales of cell processing devices, CRO business and pharmaceuticals business.

In January 2014, tella established wholly owned consolidated subsidiary Tella Pharma Inc. Using this new subsidiary, we plan to obtain approval for the DC vaccine Vaccell® as a regenerative medicine product for treating cancer.

In February 2014, tella and Genaris, Inc., which has a competitive edge in developing software for genome analysis, signed an agreement to jointly establish a company, and established consolidated subsidiary GenoCipher Inc. Through this new subsidiary, we plan to enter the genetic diagnosis support business with the goal of starting a new B-to-B service for personalized medical care.

In April 2014, tella signed an agreement for a capital and business alliance with Kohjin Bio Co., Ltd. We plan to combine the extensive culture media production technology of Kohjin Bio. The aim is to speed up the development of culture media and other items that can make the cell culture more efficient. In addition, we plan to use this alliance for business operations in Japan and overseas.

In the first quarter of 2014, net sales decreased 18,726 thousand yen, or 5.4%, from one year earlier to 328,292 thousand yen. This was attributable to firm sales in the Medical Care Support Business but was held down by lower sales in the Cell Medicine Business. There was an operating loss of 106,590 thousand yen compared with operating income of 28,793 thousand yen one year earlier, because of higher selling, general and administrative expenses mainly in the Cell Medicine Business and Pharmaceuticals Business along with the full-scale development activities for obtaining approval for the DC vaccine Vaccell®. Ordinary loss was 123,960 thousand yen compared with ordinary income of 27,066 thousand yen one year earlier. The net loss was 84,147 thousand yen compared with net income of 13,455 thousand yen one year earlier.

First quarter performance by reportable segment was as follows. Prior-year comparisons are based on 2013 figures that have been revised to match the new segments.

In the first quarter of 2014, the tella Group started full-scale development activities for the purpose of receiving approval of the DC vaccine Vaccell® as a regenerative medicine product for treating cancer. In association with the start of these development activities, we have reexamined the framework for group business operations as well as the Group's administrative structure. This reexamination resulted in these development activities, which were previously part of the Cell Therapy Technology Development segment, to be included in the new Pharmaceuticals segment. In addition, to more accurately describe the activities of the previous two segments, the Cell Therapy Technology Development segment has been renamed the Cell Medicine segment and the Cell Therapy Support segment has been renamed Medical Care Support segment. As a result, beginning from the first quarter of 2014, the previous two segments were reorganized to the following three segments: the Cell Medicine, Medical Support, and Pharmaceuticals segments.

(a) Cell Medicine Business

In this business segment, we provide unique cancer treatment technologies and know-how, chiefly the DC vaccine Vaccell®, to contracted medical institutions.

To provide information to patients, we held cancer treatment seminars jointly with contracted medical institutions in the prefectures of Hokkaido, Akita, Miyagi, Tokyo, Kanagawa, Aichi, Kyoto, Hyogo, Hiroshima, and Fukuoka.

Regarding sales activities targeting medical institutions across Japan, we entered into client medical institution agreements with following medical institutions: Hakusan-dori Clinic (Koto-ku, Tokyo) in January 2014, and Tokyo Ginza SHINTANI Oral & Maxillofacial Surgery Clinic in March 2014.

Due to all of these activities, there were approximately 300 cases during the first quarter (Jan-Mar) of 2014 in which the DC vaccine Vaccell® was used. This raises to about 7,900 the total number of DC vaccine therapy cases since tella was established.

Segment sales for the first quarter decreased 26,626 thousand yen, or 9.6%, from one year earlier to 251,347 thousand yen because of slower growth in the number of cases. Profits were affected mainly by the decline in sales, higher research and development expenses, and an increase in selling, general and administrative expenses including advertising expenses. As a result, operating loss totaled 55,979 thousand yen, compared with an operating income of 22,027 thousand yen one year earlier.

(b) Medical Support Business

Activities in this segment include the operation of cell processing facilities by contract for research and medical institutions, the provision of maintenance and management services for these facilities, sales of replacement supplies and cell processing devices, CRO business and others.

Segment sales for the first quarter increased 92,232 thousand yen, or 133.6%, from one year earlier to 161,288 thousand yen. This was mainly due to the strong sales of cell processing devices. Profits were affected mainly by an increase in selling, general and administrative expenses due to the establishment of a subsidiary. As a result, operating loss totaled 5,913 thousand yen, compared with an operating income of 6,766 thousand yen one year earlier.

(c) Pharmaceuticals Business

Activities in this segment include the development activities for the purpose of receiving approval of the DC vaccine Vaccell® as a regenerative medicine product for treating cancer.

Thus far, tella has been working on to gather scientific evidence about the DC vaccine Vaccell®. In January 2014, tella established subsidiary Tella Pharma Inc. for the purpose of promoting development activities to obtain approval for the DC vaccine Vaccell® as a regenerative medicine product.

As a result, operating loss for the first quarter totaled 38,778 thousand yen.

(2) Explanation of Financial Position

Total assets increased 1,389,325 thousand yen from the end of the previous fiscal year to 3,776,559 thousand yen as of the end of the first quarter of the current fiscal year. Current assets increased 1,224,440 thousand yen to 2,767,951 thousand yen, mainly due to an increase in cash and deposits resulting from No. 8 and No. 9 issues of stock acquisition rights and loans from financial institutions. Non-current assets increased 164,885 thousand yen to 1,008,608 thousand yen, mainly as a result of the new acquisition of non-current assets due to the establishment of new basic affiliated medical institutions, and the recording of goodwill due to the business transfer to the consolidated subsidiary TITAN Co., Ltd.

Total liabilities increased 116,348 thousand yen to 974,388 thousand yen. Current liabilities increased 136,834 thousand yen to 489,119 thousand yen, mainly as a result of an increase in short-term loans payable from financial institutions, and an increase in notes and accounts payable-trade associated with sales of cell processing devices in the Medical Care Support Business. Non-current liabilities decreased 20,485 thousand yen to 485,268 thousand yen.

Net assets increased 1,272,977 thousand yen to 2,802,171 thousand yen, and shareholders' equity ratio was 72.2%.

(3) Explanation of Consolidated Forecast and Other Forward-looking Statements

There are no revisions to the forecast in the Consolidated Financial Results for the Fiscal Year Ended December 31, 2013 [Japanese GAAP] that was announced on February 7, 2014.

Forecasts regarding future performance in these materials are based on assumptions judged to be valid and information available to the Company at the time these materials were created. Consequently, these statements incorporate many uncertainties. Actual performance may differ from these forecasts for a number of reasons.

2. Matters Related to Summary Information (Notes)

(1) Changes in Significant Subsidiaries during the Period

Not applicable.

(2) Application of Special Accounting Methods for Presenting Quarterly Consolidated Financial Statements

Not applicable.

(3) Changes in Accounting Policies and Accounting-based Estimates, and Restatements

Not applicable.

3. Quarterly Consolidated Financial Statements**(1) Quarterly Consolidated Balance Sheet**

(Thousands of yen)

	FY12/2013 (As of Dec. 31, 2013)	First quarter of FY12/2014 (As of Mar. 31, 2014)
Assets		
Current assets		
Cash and deposits	1,080,109	2,397,442
Notes and accounts receivable-trade	273,120	240,276
Lease receivables	-	3,152
Raw materials	4,237	5,544
Work in process	-	10,000
Prepaid expenses	61,566	43,227
Deferred tax assets	23,736	21,986
Income taxes receivable	26,034	26,049
Advances paid	54,204	121
Other	20,752	20,240
Allowance for doubtful accounts	(250)	(90)
Total current assets	1,543,510	2,767,951
Non-current assets		
Property, plant and equipment		
Buildings, net	212,325	240,308
Tools, furniture and fixtures, net	187,493	240,465
Leased assets, net	26,442	25,545
Construction in progress	37,421	-
Total property, plant and equipment	463,681	506,319
Intangible assets		
Software	15,595	83,223
Software in progress	74,103	-
Goodwill	-	27,424
Right of using patent	10,291	9,166
Other	-	7,658
Total intangible assets	99,991	127,472
Investments and other assets		
Investment securities	136,750	136,750
Lease deposits	107,302	108,296
Insurance funds	11,639	11,652
Deferred tax assets	22,495	62,059
Long-term lease assets	-	54,497
Other	1,863	1,560
Total investments and other assets	280,050	374,815
Total non-current assets	843,723	1,008,608
Total assets	2,387,234	3,776,559

(Thousands of yen)

	FY12/2013 (As of Dec. 31, 2013)	First quarter of FY12/2014 (As of Mar. 31, 2014)
Liabilities		
Current liabilities		
Notes and accounts payable-trade	41,071	119,989
Short-term loans payable	-	90,000
Current portion of bonds	73,200	46,500
Current portion of long-term loans payable	122,500	108,800
Lease obligations	16,437	14,382
Asset retirement obligations	6,000	-
Accounts payable-other	57,605	91,204
Income taxes payable	13,131	2,023
Other	22,339	16,219
Total current liabilities	352,285	489,119
Non-current liabilities		
Bonds payable	40,000	30,000
Long-term loans payable	382,500	357,500
Lease obligations	11,998	21,086
Long-term lease deposited	50,537	50,537
Asset retirement obligations	10,924	17,983
Other	9,793	8,161
Total non-current liabilities	505,754	485,268
Total liabilities	858,039	974,388
Net assets		
Shareholders' equity		
Capital stock	652,908	1,332,178
Capital surplus	524,585	1,203,855
Retained earnings	273,584	189,436
Treasury shares	(270)	(270)
Total shareholders' equity	1,450,808	2,725,200
Subscription rights to shares	16,978	8,438
Minority interests	61,407	68,532
Total net assets	1,529,194	2,802,171
Total liabilities and net assets	2,387,234	3,776,559

(2) Quarterly Consolidated Statements of Income and Comprehensive Income**Quarterly Consolidated Statement of Income
For the Three-month Period**

	(Thousands of yen)	
	First three months of FY12/2013 (Jan. 1 – Mar. 31, 2013)	First three months of FY12/2014 (Jan. 1 – Mar. 31, 2014)
Net sales	347,019	328,292
Cost of sales	118,771	131,109
Gross profit	228,247	197,183
Selling, general and administrative expenses	199,453	303,773
Operating income (loss)	28,793	(106,590)
Non-operating income		
Interest income	105	402
Rent income of real estate	19,227	19,412
Subsidy income	147	432
Other	176	167
Total non-operating income	19,656	20,415
Non-operating expenses		
Interest expenses	1,377	1,669
Interest on bonds	529	287
Rent cost of real estate	19,227	19,412
Share issuance cost	-	5,384
Guarantee commission	250	166
Other	-	10,863
Total non-operating expenses	21,383	37,784
Ordinary income (loss)	27,066	(123,960)
Income (loss) before income taxes and minority interests	27,066	(123,960)
Income taxes-current	4,857	676
Income taxes-deferred	6,602	(37,813)
Total income taxes	11,460	(37,137)
Income (loss) before minority interests	15,606	(86,822)
Minority interests in income (loss)	2,150	(2,674)
Net income (loss)	13,455	(84,147)

**Quarterly Consolidated Statement of Comprehensive Income
For the Three-month Period**

	(Thousands of yen)	
	First three months of FY12/2013 (Jan. 1 – Mar. 31, 2013)	First three months of FY12/2014 (Jan. 1 – Mar. 31, 2014)
Income (loss) before minority interests	15,606	(86,822)
Other comprehensive income		
Total other comprehensive income	-	-
Comprehensive income	15,606	(86,822)
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	13,455	(84,147)
Comprehensive income attributable to minority interests	2,150	(2,674)

(3) Notes to Quarterly Consolidated Financial Statements**Going Concern Assumption**

Not applicable.

Significant Changes in Shareholders' Equity

Following the exercise of subscription rights to shares, capital stock and capital surplus increased 679,270 thousand yen each during the first three months of FY12/2014, to 1,332,178 thousand yen and 1,203,855 thousand yen, respectively, at the end of the first quarter of the current fiscal year.

Segment and Other Information

I First three months of FY12/2013 (Jan. 1 – Mar. 31, 2013)

1. Information related to net sales and profit or loss for each reportable segment

(Thousands of yen)

	Reportable segment				Total	Adjustments	Amounts shown on quarterly consolidated statement of income
	Cell Medicine	Medical Support	Pharmaceuticals	Subtotal			
Net sales							
External sales	277,973	69,045	-	347,019	347,019	-	347,019
Inter-segment sales and transfers	-	10	-	10	10	(10)	-
Total	277,973	69,055	-	347,029	347,029	(10)	347,019
Segment profit	22,027	6,766	-	28,793	28,793	-	28,793

Note: Total segment profit is adjusted to be consistent with operating income shown on the quarterly consolidated statement of income.

II First three months of FY12/2014 (Jan. 1 – Mar. 31, 2014)

1. Information related to net sales and profit or loss for each reportable segment

(Thousands of yen)

	Reportable segment				Total	Adjustments	Amounts shown on quarterly consolidated statement of income
	Cell Medicine	Medical Support	Pharmaceuticals	Subtotal			
Net sales							
External sales	251,347	76,945	-	328,292	328,292	-	328,292
Inter-segment sales and transfers	-	84,343	-	84,343	84,343	(84,343)	-
Total	251,347	161,288	-	412,635	412,635	(84,343)	328,292
Segment loss	(55,979)	(5,913)	(38,778)	(100,671)	(100,671)	(5,918)	(106,590)

Notes: 1. The -5,918 thousand yen adjustment to segment loss includes an elimination for inter-segment transactions of -1,162 thousand yen and an adjustment of 7,080 thousand yen to non-current assets.

2. Segment loss is adjusted to be consistent with operating loss shown on the quarterly consolidated statement of income.

2. Information related to revisions for reportable segments

In the first quarter of 2014, the tella Group started full-scale development activities for the purpose of receiving approval of the DC vaccine Vaccell® as a regenerative medicine product for treating cancer. In association with the start of these development activities, we have reexamined the framework for group business operations as well as the Group's administrative structure. This reexamination resulted in these development activities, which were previously part of the Cell Therapy Technology Development segment, to be included in the new Pharmaceuticals segment. In addition, to more accurately describe the activities of the previous two segments, the Cell Therapy Technology Development segment has been renamed the Cell Medicine segment and the Cell Therapy Support segment has been

renamed Medical Care Support segment. As a result, beginning from the first quarter of 2014, the previous two segments were reorganized to the following three segments: the Cell Medicine, Medical Care Support, and Pharmaceuticals segments.

The segment information for the first quarter of FY12/2013 is prepared and disclosed based on the reportable segment structure after the realignment.

3. Information related to goodwill, etc. for each reportable segment

Significant change in goodwill

Goodwill was booked in the Medical Care Support segment as a result of the business combination relating to acquisition of business. The event caused an increase of goodwill by 27,424 thousand yen for the first three months of FY12/2014.

Material Subsequent Events

1. Capital and business alliance and third-party allotment

Following the Board of Directors resolution approved on April 8, 2014, tella signed an agreement for a capital and business alliance with Kohjin Bio Co., Ltd on the same day, and purchased shares of newly issued Kohjin Bio common stock through a third-party allotment.

(1) Purpose and reason for the capital and business alliance

Kohjin Bio is a pioneer in the field of culture media for growing tissue. The company has more than 20 years of experience in this field and has participated in many joint research projects with universities, research institutes and companies. Expertise in the development of new products and culture media manufacturing technology makes Kohjin Bio one of the leaders in Japan in its field.

tella and Kohjin Bio have a joint research agreement for activities that include culture media used to grow DC for DC cancer vaccine Vaccell®. The two companies decided to sign an agreement for a capital and business alliance with the goals of building a stronger framework for cooperation and conducting business operations in Japan and overseas.

(2) Overview of the business alliance

tella plans to use this alliance to combine its technologies and knowledge concerning cell cultures, which is based on technologies of The Institute of Medical Science at the University of Tokyo, with the extensive culture media production technology of Kohjin Bio. The aim is to speed up the development of culture media and other items that can make the production of DC and other cells more efficient. In addition, the two companies plan to use the newly developed culture media and other products for business operations in Japan and overseas.

(3) Overview of the capital alliance

tella purchased 18,000 shares of newly issued Kohjin Bio common stock through a third-party allotment at a cost of 180 million yen. This will give tella a 5.6% equity stake in Kohjin Bio.

(4) Profile of Kohjin Bio

(1) Name	Kohjin Bio Co., Ltd.
(2) Address	5-1-3 Chiyoda, Sakado City, Saitama
(3) Representative	Takahito Nakamura, President & CEO
(4) Main business	Development, manufacture and sale of culture media for microbe tests; development, manufacture and sale of culture media for growing tissue
(5) Capital	140 million yen
(6) Establishment	April 20, 1981

2. Cancellation of stock acquisition rights

On April 29, 2014, tella common stock reached the 30th consecutive trading day with a closing price below 1,652.7 yen on the Tokyo Stock Exchange. As a result, on April 30, 2014, the next trading day, tella purchased all stock acquisition rights in the 9th through 11th series that were issued on May 31, 2013. These stock acquisition rights were subsequently canceled on May 2, 2014 in accordance with a resolution approved the same day at an extraordinary meeting of the Board of Directors.

(1) Overview of the cancellation of stock acquisition rights

1) Resolution of the Board of Directors: May 31, 2013

2) Number of cancellations among the issued stock acquisition rights

No. 9 stock acquisition rights:	7
No. 10 stock acquisition rights:	62
No. 11 stock acquisition rights:	62

(2) Date of cancelation: May 2, 2014

In association with the cancellation, balance of stock acquisition rights as of March 31, 2014 of 8,438 thousand yen was fully reserved.

This financial report is solely a translation of "Kessan Tanshin" (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.